LAS100977 is a novel, potent β2 -agonist with rapid onset and sustained duration of action in vitro
M. Aparici, M. Gómez-Angelats, D. Vilella, J. Cortijo, E. Morcillo, C. Carcasona, A. Gavaldà, J. Beleta, C. Puig, H. Ryder, M. Miralpeix (Barcelona, València, Spain)
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Session: Bronchodilator treatment for asthma and COPD
Session type: Thematic Poster Session
Number: 1182
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Aparici, M. Gómez-Angelats, D. Vilella, J. Cortijo, E. Morcillo, C. Carcasona, A. Gavaldà, J. Beleta, C. Puig, H. Ryder, M. Miralpeix (Barcelona, València, Spain). LAS100977 is a novel, potent β2 -agonist with rapid onset and sustained duration of action in vitro . Eur Respir J 2010; 36: Suppl. 54, 1182
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Indacaterol, a novel 24-hour β2 -agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005
AZD3199: A potent and selective β2 -adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
LAS100977, a novel β2 -agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
AZD3199: A fast acting β2 -receptor agonist with a long duration of action Source: Annual Congress 2011 - Translational models of disease Year: 2011
In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agentSource: Annual Congress 2010 - Models of airways disease Year: 2010
The in vitro biology of Compound X – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Duration and onset of action of indacaterol, a novel 24-hour β2 -agonist, on isolated human bronchus Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Safety profile of a novel peptide,PIN201104,with potential to act as a disease modifying,broad spectrum treatment for asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity Source: Eur Respir J, 59 (3) 2004306; 10.1183/13993003.04306-2020 Year: 2022
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
The in vitro biology of PF-00610355 – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough Source: Eur Respir J, 56 (6) 2001387; 10.1183/13993003.01387-2020 Year: 2020
Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011